Amgen Gets FDA Approval for RIABNI, Methotrexate Combination

Amgen says the FDA has approved RIABNI in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis.

• Combination aimed at those who have had an inadequate response to one or more tumor necrosis factor antagonist therapies
• RIABNI is already approved for the treatment of adult patients with Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Granulomatosis with Polyangiitis, and Microscopic Polyangiitis
• Amgen shares climb about 0.75% in pre market trading

To view the source of this information click here

To contact the reporter on this story:
Georgi Azar in New York at gazar4@bloomberg.net

To contact the editors responsible for this ...